A pharmaceutical company is voluntarily recalling more than 3,700 bottles of blood pressure medication because of concerns about efficacy. Federal regulators announced the action last month, focusing attention on whether the affected tablets met required dissolution standards.

The U.S. Food and Drug Administration detailed the recall in an enforcement report. It applies to Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets that were distributed across the United States.

The affected products include 3,528 bottles containing 30 tablets each and 216 bottles containing 90 tablets each. Together, those quantities account for more than 3,700 bottles included in the voluntary recall.

According to the information released by regulators, the medication was distributed nationwide between Nov. 21, 2025, and April 27, 2026. The distribution period covers bottles included in both of the identified package sizes.

The medication was recalled in October after the Olmesartan Medoxomil component failed to meet dissolution testing requirements. California’s Board of Pharmacy provided the explanation for the recall and identified the failed testing requirement.

Dissolution testing is used to assess the quality of a drug by examining how effectively it dissolves in liquid. The testing also evaluates how the medication releases its active ingredients after being placed in liquid.

Pharmaceutical technology company Pion provided that description of dissolution testing and its role in evaluating drug quality. In this recall, the testing result raised concerns about the efficacy of the affected blood pressure medication.

The recall does not involve every bottle of blood pressure medication or every product made for that purpose. The FDA enforcement report specifically identifies Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets in the listed quantities.

Macleods Pharmaceuticals initiated the voluntary recall on Oct. 7. That action came after the product failed to satisfy the dissolution testing requirements cited by California’s Board of Pharmacy.

The recall was subsequently designated as Class II on Oct. 26. That federal classification describes a situation in which using the affected products carries a remote probability of causing serious adverse health consequences.

The Class II designation provides the stated regulatory assessment of the potential health risk associated with the recalled tablets. It does not remove the efficacy concern that prompted the voluntary action involving thousands of bottles.

The chronology outlined in the reports begins with nationwide distribution between Nov. 21, 2025, and April 27, 2026. Macleods Pharmaceuticals then initiated the recall on Oct. 7, followed by the Class II designation on Oct. 26.

The FDA’s report gives precise bottle counts for the affected medication. Most of the recalled supply consists of the 3,528 bottles containing 30 tablets, while another 216 bottles contain 90 tablets.

The central issue is the product’s failure to meet dissolution testing requirements. Because that testing evaluates how a drug dissolves and releases active ingredients in liquid, the failed result prompted concerns about the medication’s efficacy.

The recall has nationwide scope because the affected medication was distributed throughout the country during the stated period. Federal regulators classified the action as carrying a remote probability of serious adverse health consequences while identifying the failed dissolution requirement behind the recall.